Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

Researchers identify key molecule that drives excess protein production in Fragile X patients' brain

Researchers identify key molecule that drives excess protein production in Fragile X patients' brain

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

Oxford BioTherapeutics, Menarini Group initiate phase I study of OBT357 (MEN1112) for AML treatment

MD Anderson study sheds light on little-known protein complex

MD Anderson study sheds light on little-known protein complex

Alliance for Balanced Pain Management established to support appropriate access to pain management

Alliance for Balanced Pain Management established to support appropriate access to pain management

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

Strategy to stem infections in livestock, endangered species

Strategy to stem infections in livestock, endangered species

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

FDA grants Orphan Drug Designation to Juno's JCAR015 leukemia T cell product candidate

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Researchers find key mechanism that could lead to new effective treatments for leukemias

Researchers find key mechanism that could lead to new effective treatments for leukemias

Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

Scientists use Rapid Heme Panel test to identify right treatment for leukemia, other blood cancers

U of T, Chematria and IBM partner to find new treatments for Ebola virus

U of T, Chematria and IBM partner to find new treatments for Ebola virus

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Actimab-A extends overall survival, reduces bone marrow blasts in older AML patients

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Researchers develop 'smart bomb' to attack B-lineage ALL

Researchers develop 'smart bomb' to attack B-lineage ALL

M2Gen, Moffitt to serve as Central Laboratory and Biorepository for The National MDS Study

M2Gen, Moffitt to serve as Central Laboratory and Biorepository for The National MDS Study

New correlation found between specific molecular features of CLL and patients with different prognosis

New correlation found between specific molecular features of CLL and patients with different prognosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.